ReviewMolecules (Basel, Switzerland)2020
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 85 citations in OpenAlex.
- Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy.Clinical pharmacology and therapeutics · 2021Trial
- Investigating Neuropharmacological Features of the Cortical Activity of Cannabidiol GWP42003 P-A Phase 1 Clinical Trial.Brain sciences · 2026Article
- Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3Epilepsia open · 2026Article
- Cannabidiol-Ion Channel Interactions Represent a Promising Preventive and Therapeutic Strategy in Hepatocellular Carcinoma.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges.Therapeutics and clinical risk management · 2026Review
- NAD(P)Archives of toxicology · 2025Article
- Beyond the hype - who uses cannabidiol for self-medication - and why: a cross-sectional study in Germany.Journal of cannabis research · 2025Article
- Orally consumed cannabinoids: the effect of carrier oil on acute tissue distribution in male C57BL/6 mice.Journal of cannabis research · 2025Article
- Unveiling cellular changes in leukaemia cell lines after cannabidiol treatment through lipidomics.Scientific reports · 2025Article
- Utilization of Cannabidiol in Post-Organ-Transplant Care.International journal of molecular sciences · 2025Review
- Cannabidiol polarizes human neutrophils toward a cancer-promoting phenotype.Frontiers in immunology · 2025Article
- Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs.Animals : an open access journal from MDPI · 2024Article
- Research and Clinical Practice Involving the Use ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Unraveling the Mechanisms of Cannabidiol's Pharmacological Actions: A Comprehensive Research Overview.Topics in current chemistry (Cham) · 2024Review
- Protective Effects of Cannabidiol (CBD) against Qxidative Stress, but Not Excitotoxic-Related Neuronal Cell Damage-An In Vitro Study.Biomolecules · 2024Article
- A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance.Neuropsychopharmacology reports · 2024Article
- Article
- A systematic study of molecular targets of cannabidiol in Alzheimer's disease.Journal of Alzheimer's disease reports · 2024Review
- The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma.Frontiers in pharmacology · 2024Review
- Sturge-Weber syndrome: updates in translational neurology.Frontiers in neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid known for its beneficial effects including antioxidant and anti-inflammatory properties. Moreover, CBD is a compound with antidepressant, anxiolytic, anticonvulsant and antipsychotic effects. Thanks to all these properties, the interest of the scientific community for it has grown. Indeed, CBD is a great candidate for the management of neurological diseases. The purpose of our review is to summarize the in vitro and in vivo studies published in the last 15 years that describe the biochemical and molecular mechanisms underlying the effects of CBD and its therapeutic application in neurological diseases. CBD exerts its neuroprotective effects through three G protein coupled-receptors (adenosine receptor subtype 2A, serotonin receptor subtype 1A and G protein-coupled receptor 55), one ligand-gated ion channel (transient receptor potential vanilloid channel-1) and one nuclear factor (peroxisome proliferator-activated receptor γ). Moreover, the therapeutical properties of CBD are also due to GABAergic modulation. In conclusion, CBD, through multi-target mechanisms, represents a valid therapeutic tool for the management of epilepsy, Alzheimer's disease, multiple sclerosis and Parkinson's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.